Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Award notice |
| Buyer: | Cardiff and Vale University Health Board |
| Main Category: | Goods |
| Procurement Method: | Direct award |
| Method Rationale: | The All Wales Medical Genomics Service (AWMGS) requires PCR mastermixes and associated reagents for B and T cell clonality testing, which are critical for diagnosing and monitoring haematological malignancies such as lymphoma. These assays must include validated clonal and polyclonal controls and a control gene to ensure accurate and reproducible results. Changing supplier would necessitate full revalidation and re-accreditation of all existing assays under UKAS ISO 15189:2022 standards—a process that is highly complex, resource-intensive, and time-consuming. This would cause significant disruption to diagnostic services, resulting in delays to patient testing and reporting. Such delays pose a serious risk to patient safety, as timely diagnosis is essential for initiating treatment and improving clinical outcomes. Any interruption could lead to missed or late diagnoses, directly endangering patient health and potentially impacting survival rates. To avoid these unacceptable risks and maintain continuity of service, a direct award is the only viable option, service resilience, and safeguarding patient care across Wales. |
| Tender Status: |
All 3 notices for this procurement, oldest first.
PROVISIONS OF PCR MASTER MIXES – CLONALITY TESTING
PROVISIONS OF PCR MASTER MIXES – CLONALITY TESTING
PROVISIONS OF PCR MASTER MIXES – CLONALITY TESTING
View Original Notice
Access the full notice on the official portal
🤝 Need a consortium or subcontracting partner?
SMEs & Primes team up to win opportunities like this. Find partners on the board.
Awarded to
| Award value: | EUR 355,550 |
| Award status: | Pending |
The All Wales Medical Genomics Service (AWMGS) is awarding a direct contract for the supply of PCR mastermixes and associated reagents required for B and T cell clonality testing. These assays are critical for diagnosing and monitoring haematological malignancies such as lymphoma and must include validated clonal and polyclonal controls, as well as a control gene, to ensure accurate and reproducible results. In addition to product supply, the contract includes technical support to maintain continuity of service. Changing supplier would require extensive revalidation and re-accreditation of all assays, which would be a major undertaking and cause significant disruption to diagnostic services. This would lead to delays in patient testing, risking late or missed diagnoses and potentially endangering patient health and outcomes. The direct award is therefore essential to safeguard patient safety, maintain compliance with UKAS standards, and ensure uninterrupted delivery of critical genomic testing services across Wales.
Published contracts in the last 12 months
153
total contracts
£137.2m
total value
£5,716,257
average contract size
Typical categories
Risk Assessment of Lightning Protection Systems
Cardiff and Vale University Health Board · WAC-638795
Bespoke Printing Services
Cardiff and Vale University Health Board · WAC-636329
Provision of Community Dental Sedation Services for Cardiff and Vale University Health Board
Cardiff and Vale University Health Board · WAC-636511
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Closed |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 2 December 2025 |
| Application Deadline: | — |
| Contract Start Date: | — |
| Contract End Date: | — |
| Contract Duration: | NaN years |
| Procurement ID (OCID): | ocds-h6vhtk-05ecf5 |
| Notice Reference: | 078933-2025 |